Physician profile
Zhen Hou
NPI 1912994872
$1,154.82
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $163 · 2021: $55.74 · 2022: $52.85 · 2023: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $140.86 | 2019-2023 | Eliquis, Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $128.89 | 2019 | |
| Amgen INC. | $95.01 | 2019-2023 | Lumakras |
| Pfizer INC. | $93.91 | 2019-2020 | |
| Janssen Biotech, INC. | $86.09 | 2019 | |
| Genentech USA, INC. | $80.31 | 2019-2023 | Tecentriq, Alecensa |
| Daiichi Sankyo INC. | $50.08 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.01 | 2019-2021 | |
| Lilly USA, LLC | $35.28 | 2019-2023 | Jaypirca, Verzenio |
| Exelixis INC. | $34.14 | 2022 | |
| Genzyme Corporation | $32.37 | 2019-2020 | |
| Emd Serono, INC. | $32.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.97 | 2020-2023 | |
| Agios Pharmaceuticals, INC. | $30.05 | 2019-2020 | |
| Celgene Corporation | $26.95 | 2019-2023 | Opdualag |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.24 | 2019 | |
| Abbvie INC. | $22.33 | 2023 | |
| Eisai INC. | $20.30 | 2019 | |
| Tesaro, INC. | $20.13 | 2019 | |
| Kite Pharma, INC. | $18.71 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.90 | 2019 | |
| Karyopharm Therapeutics INC. | $14.54 | 2020 | |
| Seagen INC. | $14.09 | 2020 | |
| Sumitomo Pharma America, INC. | $13.45 | 2023 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $12.53 | 2019 | |
| Verastem, INC. | $12.30 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhen Hou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.